<SEC-DOCUMENT>0001628280-23-027426.txt : 20230804
<SEC-HEADER>0001628280-23-027426.hdr.sgml : 20230804
<ACCEPTANCE-DATETIME>20230804091029
ACCESSION NUMBER:		0001628280-23-027426
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230804
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20230804
DATE AS OF CHANGE:		20230804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		231142374

	BUSINESS ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ovid-20230804.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:60e2ffbb-4719-499d-8568-05696a534326,g:e08be127-ce27-480f-9a02-c4d9df0aa4a2,d:a0e8c0c7821147e187a4b381cfd41ea8--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ovid-20230804</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-17">0001636651</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-18">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ovid-20230804.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia0e8c0c7821147e187a4b381cfd41ea8_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;4, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">OVID THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"> (Exact name of Registrant as Specified in Its Charter) </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38085</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-5270895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(State or Other Jurisdiction</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(IRS Employer</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">441 Ninth Avenue, 14th Floor</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">New York, New York</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">10001</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:40%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-7">646</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-8">661-7661</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-10">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-11">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-12">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:38.505%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.001 per share</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">OVID</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia0e8c0c7821147e187a4b381cfd41ea8_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2023, Ovid Therapeutics Inc. (the &#8220;Company&#8221;) issued a press release announcing Second Quarter 2023 Financial Results and Corporate Updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27.74pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="ia0e8c0c7821147e187a4b381cfd41ea8_10"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibit</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="ovid2023q2exhibit991.htm">Press Release, dated</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">August&#160;4, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia0e8c0c7821147e187a4b381cfd41ea8_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:26.19pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">OVID THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;/s/ Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General Counsel &amp; Corporate Secretary </span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-19">August&#160;4, 2023</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ovid2023q2exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i85862df840db414086e7976a29c9f964_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="img34400995_0a.jpg" src="img34400995_0a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Ovid Therapeutics Reports Second Quarter 2023 Financial Results and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Executed equity investment and initiated collaboration with Graviton Bioscience to develop highly selective ROCK2 inhibitors for rare neurological conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Expanded scientific leadership team with appointments of Chief Scientific Officer and Chief Medical Officer </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Regulatory filings for soticlestat in Lennox-Gastaut syndrome and Dravet syndrome continue to be anticipated by Takeda in its fiscal year 2024 </font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NEW YORK, August 4, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Ovid Therapeutics Inc. (NASDAQ&#58; OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;In the second quarter, we accomplished a strategic milestone for Ovid. We added a novel clinical stage program and a library of potential first-in-class and best-in-class ROCK2 inhibitors to our pipeline through an exclusive license and collaboration agreement with Graviton. We believe these ROCK2 inhibitor programs add an important therapeutic platform to our pipeline and may address the underlying causes of several neurological disorders,&#8221; said Dr. Jeremy Levin, D. Phil, MB BChir, Chairman and CEO of Ovid. &#8220;Both the ROCK2 inhibitor and KCC2 activator portfolios are platforms that we believe can become the foundation for multiple future medicines in epilepsies, seizure-related disorders and other brain diseases. Our experienced team, under the leadership of Drs. Zhong Zhong and Manoj Malhotra, as our respective Chief Scientific and Chief Medical Officers, is focused on advancing compounds with these unique mechanisms of action for seizure-related disorders. Additionally, we are investigating further indications and intend to seek development partnerships to explore the full potential of our compounds and platforms.&#34;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Clinical &#38; Research Pipeline Updates</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.8pt">OV329, a potential next generation GABA-aminotransferase (GABA-AT) inhibitor, has completed the SAD portion of a Phase 1 trial.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Company has seen no safety signals in the single ascending dose cohorts in healthy human volunteers. Ovid anticipates full Phase 1 findings in the first half of 2024, including biomarker data that may serve as a proxy for seizure reduction efficacy. Additional animal and non-clinical efficacy and toxicology studies are currently ongoing to further support clinical development and indication selection. OV329 is a more potent GABA-AT inhibitor that we believe has different physiochemical, pharmacokinetic and pharmacodynamic properties as compared to prior compounds in the class. We believe OV329 may provide significant characteristics including seizure reduction efficacy, an improved safety profile, and preferable (lower) dosing.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.8pt">Graviton collaboration for the development of novel ROCK2 inhibitors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> In May 2023, Ovid made an equity investment and entered into a license and collaboration agreement with Graviton to develop and commercialize medicines for rare neurological conditions from Graviton&#8217;s library of highly selective, ROCK2 inhibitors. In June 2023, Ovid and Graviton initiated the first Joint Development Committee under the license and collaboration agreement, which will determine preferred formulations, compounds to develop, and clinical development plans. The collaborators intend to align on the initial development program in the second half of 2023, including plans to support a potential investigational new drug application (IND) and proof of concept trial in cavernous malformations of the brain in 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.8pt">KCC2 activator portfolio and OV350 IND-supportive activities. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Ovid is conducting multiple non-clinical studies to characterize the therapeutic potential of direct activation of the potassium chloride channel 2 co-transporter (KCC2) from its library of compounds. Preclinical activities remain on track to file the lead compound, OV350, for an IND in an epilepsy indication in 2024. The Company is also conducting animal studies to explore the role of KCC2 activation in conditions such as schizophrenia, pain and other cognitive and behavioral disorders. These non-epilepsy indications may represent future development collaboration opportunities.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Takeda is executing two pivotal Phase 3 trials studying soticlestat for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). </font><font style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Takeda anticipates regulatory filings for soticlestat in its fiscal year 2024. Takeda repurchased Ovid's interest in soticlestat in 2021, and Ovid is subsequently eligible to receive regulatory and commercial milestone payments of up to $660 million, as well as royalties up to 20% on global sales, if regulatory approval is received and soticlestat is commercialized. Ovid has no ongoing obligations or costs associated with the development of soticlestat.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">General Corporate &#38; Business Update</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9.3pt">Research &#38; Development Strategy&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Ovid seeks to develop a leading pipeline of novel medicines for the potential treatment of epilepsies and seizure-related disorders. The mechanisms of action used in Ovid's compounds modulate either&#58; novel biological targets implicated in neurological disorders or validated targets for which the Company believes it can deliver potential products with preferred safety, tolerability, and efficacy relative to previously approved medicines. With three active development programs and a financial stake in a fourth program (soticlestat), Ovid's R&#38;D strategy and pipeline intends to&#58; create targeted therapies that are important to medical practice, maximize opportunities to create value for stockholders, open multiple paths to potential partnership revenue, and risk mitigate the pipeline relative to any single program. For example, in addition to its core focus on epilepsies, the Company intends to pursue collaborations to investigate compounds from its ROCK2 inhibitor and KCC2 activator platforms for neurological conditions beyond seizures. This strategy provides multiple potential therapeutic opportunities.</font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9.3pt">Financial strategy&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Ovid anticipates its cash runway should fund operations into 2025 and will seek to extend the runway beyond this period. To support this strategy, management has taken several steps, including&#58; directing its resources toward high-value R&#38;D activities, continuing to institute efforts to optimize its infrastructure, seeking development partnership programs for its novel molecules outside of its core areas of focus, and continuing to benefit from and expand licensing transactions. In the second quarter of 2023, the Company instituted cost cutting measures, which included reductions to its general and administrative (G&#38;A) functions to lower infrastructure costs and enhance efficiency as part of an ongoing operational initiative. In addition </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to its current runway projections, Ovid is eligible to receive significant additional non-dilutive capital from Takeda, if and when soticlestat is successfully approved and commercialized. Takeda has provided guidance that it anticipates filing for global regulatory approvals of soticlestat in its fiscal year 2024. </font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9.3pt">Business development activities&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Ovid&#8217;s future business development efforts are focused on exploring out-licensing opportunities for the Company's genetic programs as well as elements of its patent estate that are not needed for its development programs. Ovid intends to explore potential R&#38;D collaborations to advance development opportunities for its KCC2 portfolio in non-core indications. Additionally, Ovid will explore commercial partnerships for some of its programs in territories outside the United States.</font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9.3pt">Management updates&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Ovid appointed Drs. Zhong Zhong and Manoj Malhotra to serve as its Chief Scientific Officer and Chief Medical Officer, respectively. They replace Dr. Claude Nicaise following his planned retirement last spring. Additionally, Meg Alexander was promoted to Chief Strategy Officer and will Chair the Joint Development Committee overseeing the development of ROCK2 inhibitors with Graviton. </font></div><div><font><br></font></div><div id="i85862df840db414086e7976a29c9f964_4"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Second Quarter 2023 Financial Results</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash, cash equivalents and marketable securities as of June&#160;30, 2023, totaled $96.5 million.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the second quarter 2023, Ovid executed several non-routine non-operating cash expenditures. These included a $10 million equity investment in Graviton Bioscience as part of the research collaboration entered into in May 2023, and $3.5 million in funding for annual research and development activities conducted by Gensaic Therapeutics, Inc. as part of Ovid's collaboration with Gensaic.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Revenue was $75,000 for the three months ended June&#160;30, 2023, as compared to no revenue recognized in the same period of 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were $6.0 million for the three months ended June&#160;30, 2023, which was consistent with the same period in 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $8.2 million for the three months ended June&#160;30, 2023, as compared to $8.3 million for the same period in 2022. Second quarter expenses included severance costs following a headcount reduction that primarily impacted roles within Ovid's G&#38;A functions in June 2023.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total operating expenses were $14.2 million in the three months ended June&#160;30, 2023, as compared to $14.3 million for the same period last year. These include non-recurring or non-cash operating expenses of $3.8 million, comprised of $1.9 million in stock-based compensation, $1.1 million in severance expenditures from the organizational changes executed in June 2023, and amortization and depreciation expenses of $700,000. These compare to a total of $2.3 million in non-recurring or non-cash operating expenses incurred in the same period in 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ovid reported a net loss of $12.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.18, for the three months ended June&#160;30, 2023, as compared to a net loss of $14.6 million, or basic and diluted net loss per share attributable to common stockholders of $0.21, for the same period in 2022.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i85862df840db414086e7976a29c9f964_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Ovid Therapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and intractable brain disorders with courageous science. Ovid&#8217;s focused pipeline of small molecule candidates seeks to meaningfully improve the lives of people and families affected by rare epilepsies and seizure-related disorders. Ovid seeks to develop&#58; GV101, a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations&#59; OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures&#59; and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. The Company's ROCK2 inhibitor and KCC2 activator portfolios have the potential to treat neurological conditions beyond seizures, and represent potential future collaboration opportunities for the Company. Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com.</font></div><div style="text-align:justify"><font><br></font></div><div id="i85862df840db414086e7976a29c9f964_10"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release includes certain disclosures that contain &#8220;forward-looking statements,&#8221; including, without limitation&#58; statements regarding the Phase 1 study in healthy volunteers for OV329&#59; the potential use of OV329, GV101 and OV350&#59; the clinical and regulatory development of our programs, including the anticipated timing of clinical data&#59; the likelihood that data for OV329, GV101 and OV350 will support future development and therapeutic potential&#59; the potential development of GV101 and the library of ROCK2 inhibitors and OV350 and other KCC2 compounds in Ovid&#8217;s library&#59; the suitability of Ovid&#8217;s library of novel, direct KCC2 transporter activators and the library of ROCK2 inhibitors for a range of formulations and administrations&#59; the timing for filing of Ovid&#8217;s IND applications&#59; the potential development and therapeutic opportunity of GV101 and other Rho&#47;Rho associated coiled-coil containing protein kinase 2 inhibitors&#59; and the potential safety, selectivity and potency of our pipeline programs, including GV101 and other ROCK2 inhibitors&#59; the timing for the completion of Takeda&#8217;s two pivotal Phase 3 trials evaluating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome&#59; and the duration of Ovid&#8217;s expectations regarding its cash runway and the expectation that it will support the advancement of Ovid&#8217;s pipeline. You can identify forward-looking statements because they contain words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expected,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;seek,&#8221; &#8220;strive&#8221; and &#8220;will,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid&#8217;s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid&#8217;s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid&#8217;s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption &#8220;Risk Factors&#8221; in Ovid&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on May 5, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</font></div><div id="i85862df840db414086e7976a29c9f964_13"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br>June 30, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br>June 30, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br>June 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br>June 30, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,160&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,366&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,998,766&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,046,670&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,613,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,878,939&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,257,617&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,591,964&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,137,820&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246,982&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,304,287&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,205,447&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,016,759&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,171,982)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,304,287)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,064,286)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,571,393)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,652&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284,127)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,076)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,534,181</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,458</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,512,479</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,236</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,534,181</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,458</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,512,479</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,236</font></td></tr></table></div><div id="i85862df840db414086e7976a29c9f964_16"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Select Condensed Balance Sheet Data</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#bf2115;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,517,400&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,001,411&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,029,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,389,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total assets</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,229,764&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,265,814&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total stockholder's equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,698,675&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,272,564&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital defined as current assets less current liabilities</font></div></td></tr></table></div><div id="i85862df840db414086e7976a29c9f964_19"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investors &#38; Media</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Argot Partners</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maeve Conneighton</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">212-596-7231</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ovid&#64;argotpartners.com </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ovid-20230804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:60e2ffbb-4719-499d-8568-05696a534326,g:e08be127-ce27-480f-9a02-c4d9df0aa4a2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ovid="http://www.ovidrx.com/20230804" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20230804">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230804_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ovidrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>ovid-20230804_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:60e2ffbb-4719-499d-8568-05696a534326,g:e08be127-ce27-480f-9a02-c4d9df0aa4a2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ovidrx.com/role/Cover" xlink:type="simple" xlink:href="ovid-20230804.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/Cover" xlink:type="extended" id="i590ffcba0c0141bda1b8a8c3e5bbc2ce_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_094d6abb-b3e0-469e-a39c-a771c413c421" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_883c7621-b4c2-49d5-8be7-4c7cc582e918" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_094d6abb-b3e0-469e-a39c-a771c413c421" xlink:to="loc_dei_DocumentPeriodEndDate_883c7621-b4c2-49d5-8be7-4c7cc582e918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_224ce26e-c0e2-4bf9-ab8b-4df9696a5b55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_094d6abb-b3e0-469e-a39c-a771c413c421" xlink:to="loc_dei_DocumentInformationTable_224ce26e-c0e2-4bf9-ab8b-4df9696a5b55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ovid-20230804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:60e2ffbb-4719-499d-8568-05696a534326,g:e08be127-ce27-480f-9a02-c4d9df0aa4a2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_b4f0386f-4a74-4d73-b86d-362b4477bc7c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ba7644b9-d2d0-43f1-bebb-f42f71ddfa94_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d69e2ce9-8bca-4d1a-afcb-b876ce92175c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5c0b2046-64e6-449c-b35d-01f21d8b4c2a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7b4acbe7-b876-406d-bef6-5a78e752401b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_9a4c76c8-ed54-4457-8f7f-920d871319ae_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0e59fca5-0211-4318-9f17-f46bca918591_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7c42de7d-14b1-456d-8230-8b13fb19de7c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_399ccef0-9732-4f63-89f8-a00ce07f396c_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fb5967ec-7a57-437e-9aab-f962ebff6830_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_79d12072-cbaa-41a4-8db9-40fdfd958417_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_38086d33-4372-4564-a42c-3ccc8720ad7c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a754ec3b-18b3-427a-9a95-ba1cbf7286de_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_df26dbb5-74e0-472e-8685-90a3436c4ee0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3f00b431-6100-4563-b0e4-60f578708098_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_48ad90b8-e19f-47a5-837f-77a683d563af_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_136b6bef-3cd1-40c1-a4b0-44f99658b233_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_44e76b6b-eb29-4a4a-955d-772f8ebc747f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f27c2f2a-6945-446a-8e56-5a4acc5983bc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_590411f5-e135-4674-92f3-8048f3087e74_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1dd71b37-f9c0-409a-9cab-c7149c012f3e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_c4abad6b-a128-4db3-bfc3-1f4f5ae6a609_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6d01d4f6-593f-46a6-9ac8-f487d0fde408_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d4e87af8-f530-4cad-9025-b8fc39db163e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2816ad34-d6d3-4269-a43e-d1ec6a278669_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ovid-20230804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:60e2ffbb-4719-499d-8568-05696a534326,g:e08be127-ce27-480f-9a02-c4d9df0aa4a2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/Cover" xlink:type="simple" xlink:href="ovid-20230804.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6cfbbec0-969c-4c76-b29a-c85996973fd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_DocumentType_6cfbbec0-969c-4c76-b29a-c85996973fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e156b031-4665-43d3-b549-15e240f42050" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_DocumentPeriodEndDate_e156b031-4665-43d3-b549-15e240f42050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dc1b6bbc-8a7a-42de-94ee-90db81771c7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityRegistrantName_dc1b6bbc-8a7a-42de-94ee-90db81771c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_384bf1e1-61a5-40f5-9fa6-e589a69188e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityIncorporationStateCountryCode_384bf1e1-61a5-40f5-9fa6-e589a69188e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c948566-371a-476f-8b6b-517c895c6e62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityFileNumber_4c948566-371a-476f-8b6b-517c895c6e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_542ad5f8-781c-4cb2-8e5c-1278047c4e4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityTaxIdentificationNumber_542ad5f8-781c-4cb2-8e5c-1278047c4e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_59918446-e5e5-481e-82ea-f95f69583576" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityAddressAddressLine1_59918446-e5e5-481e-82ea-f95f69583576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_262fae1f-3ba2-4d51-9836-024fbc64d86f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityAddressAddressLine2_262fae1f-3ba2-4d51-9836-024fbc64d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b2640ab2-ee29-4ec0-98e4-d6e728ca0e47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityAddressCityOrTown_b2640ab2-ee29-4ec0-98e4-d6e728ca0e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_571a56a7-abf6-4c88-b752-d39491aeb427" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityAddressStateOrProvince_571a56a7-abf6-4c88-b752-d39491aeb427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_43e8aea2-fe02-441a-912e-69b32f732d1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityAddressPostalZipCode_43e8aea2-fe02-441a-912e-69b32f732d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ce35a131-7988-4d15-a7f2-df7c7964cbf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_CityAreaCode_ce35a131-7988-4d15-a7f2-df7c7964cbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0f005f82-f94e-460e-86be-31b48990755d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_LocalPhoneNumber_0f005f82-f94e-460e-86be-31b48990755d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b2f98336-6f61-4363-a07b-513da1bf79aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_WrittenCommunications_b2f98336-6f61-4363-a07b-513da1bf79aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c9f387f1-cbe6-45c4-88ed-11e713e57070" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_SolicitingMaterial_c9f387f1-cbe6-45c4-88ed-11e713e57070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_3f6b3dec-0873-4467-9d50-ff9cc4b8ecab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_PreCommencementTenderOffer_3f6b3dec-0873-4467-9d50-ff9cc4b8ecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ad99813c-a34c-4949-95e8-e5bf231a36b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ad99813c-a34c-4949-95e8-e5bf231a36b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_10c85d53-f213-4fd1-928a-e953b16e5669" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_Security12bTitle_10c85d53-f213-4fd1-928a-e953b16e5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_474a1900-e6ac-4947-abe3-37b917532156" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_TradingSymbol_474a1900-e6ac-4947-abe3-37b917532156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d5e2b4ad-9864-4a46-a533-fa9a7f2f7e83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_SecurityExchangeName_d5e2b4ad-9864-4a46-a533-fa9a7f2f7e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bbbcbc01-5c93-44b2-862d-a657d940e9df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityEmergingGrowthCompany_bbbcbc01-5c93-44b2-862d-a657d940e9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_02c9f50a-73a5-4cad-8a32-abe90edcbf97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_EntityCentralIndexKey_02c9f50a-73a5-4cad-8a32-abe90edcbf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_707fb01b-1151-481b-921d-8b483926d285" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_AmendmentFlag_707fb01b-1151-481b-921d-8b483926d285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_224ce26e-c0e2-4bf9-ab8b-4df9696a5b55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ddd1d8c7-d226-4d42-9ed7-89bbc87f9dda" xlink:to="loc_dei_DocumentInformationTable_224ce26e-c0e2-4bf9-ab8b-4df9696a5b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_094d6abb-b3e0-469e-a39c-a771c413c421" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_224ce26e-c0e2-4bf9-ab8b-4df9696a5b55" xlink:to="loc_dei_DocumentInformationLineItems_094d6abb-b3e0-469e-a39c-a771c413c421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_883c7621-b4c2-49d5-8be7-4c7cc582e918" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_094d6abb-b3e0-469e-a39c-a771c413c421" xlink:to="loc_dei_DocumentPeriodEndDate_883c7621-b4c2-49d5-8be7-4c7cc582e918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img34400995_0a.jpg
<TEXT>
begin 644 img34400995_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "G @8# 2(  A$! Q$!_\0
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M:*\#5C%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU2X4Y(Y_Y9J>I[D8]:\V^ ?P=\3_ +9'QJ!O?-_L6&5)M8OE.U+6VSQ$GHS
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MBO+=R,%DD0,I(['!Z5^=_P#P5H^)QN-6\&_#^WF;9;H^LWT6 5+,3' <]=P
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M '>DHGH'[//P!\/?LY_#^W\-Z&GG3,1-?ZA(,27<Y&"[>@[ =A7J-?">I?\
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MOS:_:@^)@^+WQ\\9^)XI%DL[B^:"T=,[6MX@(HVP>FY5!^I-:?[.O[1-_P#
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MRA"%FUO<GE-Y55555&% P!3J**^**/R2_P""J[!?VD-)R<?\4[;]_P#IM/7
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MW]F_]D[QA^T-XHM+6RL9M+\-JV^\UJXB*Q1QC&0F?O.0> .._:O/?BWX:LO
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M444 %%%% !1110 4444 %%%% !1110 4444 )2<=*=24K >7_'SX ^&/VB/
MUSX>\1VX649>RU&)1Y]G-CAT/\UZ$5^5&DWOQ#_X)\_M!I#>,_D*ZFXCB/\
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MQ4/A7]G[XU?'3P?%KGQ'^*VK>$[C5A'<KX?T*)$BM4VC8K<<-P"0.YKD-+^
MEW\#?VS_ ((QW7C36/&/]I1ZNRMJS F#9:-]S'KNY^@K6"]Z?-4N[/36VP'L
M/_!1Q2W[)OB@+P3=6.#Z'[3'@UW?PF_9P\(?#_P7:V5[I-EX@UJY/VS4]7U"
M!9IKR[< R2%F!.">@Z  5PW_  4:_P"34?$O_7W8_P#I5'7TG9_\>D'^XO\
M*N*52<,-!)V5W^@'PW\>_A_:_L^_M<?!SQ]X*L(]*M/%&I#0=8M+=0ENYD94
M#D#^(J[''0&(&O2_V_/'&OZ-\+M$\'>%+E;;Q%XXUF#086\S8XBDSYA5NV3L
M0GT<U!^W)<1?;?@9;;U^TR?$+361,_,5!;)'MDK^=><_\%(_"MUXR^(OP!T>
M.\N-.MM1UR73WOK;[]N\LENJNO\ M ;B/I7;1_?3HRJ/H]?2[0'U!\._V=_
M?PW\&Z9X?T_PQILT5I L3SW%LDDL[8&YW8C)+')-?.5QX'C_ &=OV_/"$OAB
M"'1O"7Q&L+N&_LT/[IKN)6D8HG1#GR>?]M_6AO\ @FW=?]%K\9?]_%K=^''_
M  3[M_ GQ,\-^,;SXD>(?$EQH<YGM[74@CIDK@@'J,\=/2HC.G'F<JO-=/2S
M P/V\1_QD1^R]D=/$K'_ ,CVE?;?:OB7]O'_ ).(_9>_[&5O_2BTK[:]:Y*_
M\&EZ/\V,^)?A7C_AZ1\6_7_A&H/_ $"QK._X*F>$]$TKX+Z!J-EI%E::A<^*
M;?S[J&W5)9=T4Y;<P&3D\G-:/PK_ .4I'Q<_[%J#_P! L:E_X*N?\D$\+C_J
M:;7_ -$3UWPDXXNE9](_D+H?7/AGPCHGAFWW:1I%CI9G1/--G L6_ XS@<XR
M?SKY7\"_\I.?B!Z_\(=%_P"AVU?7UG_QZP?[B_R%?(/@7_E)Q\0/^Q.B_P#0
M[:N"@VU5;?V?U0$7[<2:A\5/B?\ !_X*V-X(]-\1W\E_K=NK^6[VL&&^]_NB
M8X[E5KZ3TKX->!-%TFWTRS\(Z/'8V\2PI']CC/R*,*"2.>/6OFGXLV\Z_P#!
M2[X,SLK?9WT&\5&_A+"*ZW#ZX85]EU=:4J=*E&+LK7^;; ^3_P!GOX+^(/@'
M^U%\0=%T32I;3X1ZWI\>J6+;MT4%X&53"N3E3\TIQ_=">E<S\;;/PUXC_P""
M@7@/2_B#*I\.6OALW>DVU\0+.6^$TA^?=\N=JYY[JGK7VC]HB-QY'FIY^W?Y
M6X;MO3..N/>O.?CC^S[X._:!\.II?BJP:22W.^TO[=O+N+5L@Y1QR,XY'<4J
M>(_>\]3JK7Z[6N!7^*7[./@7XG>!=5\.W7AW3;3[7;O%!=V]JBR6TF#LD4@=
M5;!JA^R;X1\:> /@?H/AGQX(SKFDF2U66.X\X20!R8B6QV4A<?[(KY_UC1?C
M[^QO8G4](UG_ (6S\.+'=)<V&H#%]:6ZKDL&[@$LW']T<'-?57P:^+&C_&_X
M;Z+XRT/>ECJ41;R9<>9#(I*NC8[A@1[C![TZT:D:5N;FA??S_0#NJ***\\ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY
M(UFC9&&58%2/8U)10!^:O[.G[(GCWX3?MP-J<>@367@72[N_EM]3DF#12VLD
M<BPJ#G+/^\3((XP?2OTIVBBEKKQ6*GBY*4]TD@&;:=BBEKC ****8!1110 5
M'<?ZB3_=/\JDI* /CO\ X)CL&^$?CH@YQXRO>G_7*"OL2J>EZ+I^APR1:=8V
M]C%(YD=+>)8PS'&6( Y/ Y]JNUM6J>UJ.?<#XD^%3#_AZ1\7%SS_ ,(S"<?\
M L:^U+S_ (\Y_P#KFW\J@AT+3;?59M3BL+:/4IEV27:Q*)77C@MC)' _(5=(
M# @C(IU:GM&GV27W(#XI_P""4;!O@#XG(.?^*INNG_7&"LKQ!<ZO^PW^T=XN
M\:3Z1>:Q\)O'DJW=_=649EETV[RS,S]]N6E;L,,!Q@5]O:3H>G:#;M!IMA;:
M? SF1H[6)8U+'J2 .O J>\L;;4K62VNX([FWD&UXID#*P]"#UKH^LIU9S<=)
M;H#YFU__ (*)?"#3]'@GT;4[SQ/JMU$S6NDZ9:L\[R;25C8?PDGC/.*]I^%/
MBS7?''PQT?7?$F@-X7UN]MFDN-*D;<8#D@<^X .#TS6Q9?#_ ,,:;=1W-IX>
MTNVN(SN2:&SC5E/J"!Q6\0#U&:PJ2I6M3C;U ^._^"8[ _"/QUM.?^*RO?\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140330890854144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OVID THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ovid-20230804_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ovid-20230804.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-17">0001636651</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-18">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">OVID THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38085</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-5270895</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c-1" id="f-7">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-8">661-7661</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">OVID</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-16">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-19">2023-08-04</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M QP7-BMSH^ MAS@S',LWIOJN 2G[P(V.8?>'L.!,V!/=$Z]S0P(O:/TSV@6
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M;%!+ 0(4 Q0    ( $Y)!%=[0>"W[@   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $Y)!%>97)PC$ 8  )PG
M   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ 3DD$5_5$$-()!   4P\  !@              ("!#0@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $Y)!%>?H!OPL0(  .(,
M   -              "  4P,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M3DD$5Y>*NQS     $P(   L              ( !* \  %]R96QS+RYR96QS
M4$L! A0#%     @ 3DD$5ZK$(A8S 0  (@(   \              ( !$1
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $Y)!%<D'INBK0   /@!   :
M              "  7$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( $Y)!%=ED'F2&0$  ,\#   3              "  582  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  * 3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>18</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ovid-20230804.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-60548-EntityAddressAddressLine1-Missing] Submission type 8-K should have a non-empty value for EntityAddressAddressLine1 in the Required Context. ovid-20230804.htm </Log>
    <Log type="Warning">[dq-60548-EntityAddressCityOrTown-Missing] Submission type 8-K should have a non-empty value for EntityAddressCityOrTown in the Required Context. ovid-20230804.htm </Log>
    <Log type="Warning">[dq-60548-EntityAddressPostalZipCode-Missing] Submission type 8-K should have a non-empty value for EntityAddressPostalZipCode in the Required Context. ovid-20230804.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="ovid-20230804.htm">ovid-20230804.htm</File>
    <File>ovid-20230804.xsd</File>
    <File>ovid-20230804_def.xml</File>
    <File>ovid-20230804_lab.xml</File>
    <File>ovid-20230804_pre.xml</File>
    <File>ovid2023q2exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ovid-20230804.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 19
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "ovid-20230804_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ovid-20230804.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ovid-20230804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ovid-20230804_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ovid-20230804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 18,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ovid",
   "nsuri": "http://www.ovidrx.com/20230804",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230804.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ovidrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230804.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-23-027426-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-027426-xbrl.zip
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M0AA-UM9G*_.[+?O;J+9&C+%)_>F#Z2)M,[1NT>3W7S]\E5=ZSD&:+4J>R6J
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MU9GGXI,Q]M9%42(2H0V(I$( 0XD Q\*6?6P82V(JPBARS0V'!AM;>K!X@=P
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M?\)5R->+-Y%'K0_*]I653O)CYW.@RY@(R!1"(,A 9% SM,9G39+MWDOQ<A@
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M<%Z0)*&!1:0%%C$!2P@BJ\AO*3F[F5F6 6LP',9^M'C"WZ8 ,BR]C$3@OIR
M@![YT:5(7J)XPJB;'8%J@BR&>_&-QV20 1NLI,R*Q(5.VG3*1_A$@:BGJX_<
MD&73/^=)J<UGHC5)!#]O\2G0YYC[EWRAGMU]9J^Q.?=K<XK0==VOR;W;JHX
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M<L1$1T4?%OJCS7Z%-^5S+8D+<"W S8,* >9\3O 7<%D1IBF&L#2?+-+28"J
M7[CE>!$M6E3A<+X9:UX*0F)?155:&NQ>(5XUM@%&0. RJN)C1J]8!96!0D4'
MR)W+OZ-X#NA9<L#+7(:5&)4;S5#;70@3XYR#NH^2:F2/)JLT6]>L21$H3@3H
M:H6*T@3.JKJSKO0C$N8LU%)\-\&2>U!=-Q7[.#W\=S_E#WN>VWIEEZ<=%<@R
M5DB05WD)+IB\@%V=>\Y=;=X4R3Y%H*MY4-QDFQ*A1S]_.'NY-AUZ].[LY7IU
M>8^$6I_X,$2IAA&2K=+!ZU*W[3RU"[LQ2URDIT=([EL-=6"'TK-+0\&CMD9/
MN597V40!YM41 '" 9Q)]4-!"H"P%ZHK*'.O(M9*/B?FBJ%3(8GSZF\&@@S>
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M5O/(&64[UL#N6KV1TW#JP#G5M4;#D37NCA]0'&H]KGP8-G=SL[0OLKIK2/%
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MO[T=0BGW([]/*0Q?1?&>Q&_H]'9UJ1[S9ENWQ(/?4;L@\L,[8=.(VP,3MUT
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M2P$"% ,4    " !.2017QC3[_Y,/  "K=0  $0              @ $
M;W9I9"TR,#(S,#@P-"YH=&U02P$"% ,4    " !.2017R6,"N7,"  !H"
M$0              @ '"#P  ;W9I9"TR,#(S,#@P-"YX<V102P$"% ,4
M" !.2017R6,G.PP#  !+"P  %0              @ %D$@  ;W9I9"TR,#(S
M,#@P-%]D968N>&UL4$L! A0#%     @ 3DD$5Y_5*#%7"P  #VD  !4
M         ( !HQ4  &]V:60M,C R,S X,#1?;&%B+GAM;%!+ 0(4 Q0    (
M $Y)!%># /0[9@<  %0Y   5              "  2TA  !O=FED+3(P,C,P
M.# T7W!R92YX;6Q02P$"% ,4    " !.2017>(3YE3$A  !C& $ &
M        @ '&*   ;W9I9#(P,C-Q,F5X:&EB:70Y.3$N:'1M4$L%!@     &
-  8 C0$  "U*      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
